 This study is complementary to a multi-center, randomized, double-blind,parallel-group, placebo-controlled, variable treatment duration study comparing the efficacy and safety of BAF312 to placebo in patients with SPMS NCT01665144. Investigators will explore both immunological and neuroprotective mechanisms of BAF312 siponimod, a novel agent in the setting of a SPMS clinical trial. 